Clinical Trial Update: A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial ofInotuzumab Ozogamicin plus Rituximab for relapsed/refractory aggressive non-Hodgkin lymphoma in patients unsuitable for high-dose chemotherapy; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)
• Rituximab (rituximab)

Snippet

Sponsor: Pfizer | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: TERMINATED | Results posted: 2018-08-21